ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended				3 Months Ended		6 Months Ended				12 Months Ended		3 Months Ended			3 Months Ended	12 Months Ended			3 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2014 AstraZeneca [Member]	Jun. 30, 2013 AstraZeneca [Member]	Jun. 30, 2014 AstraZeneca [Member]	Jun. 30, 2013 AstraZeneca [Member]	Dec. 31, 2016 AstraZeneca [Member]	Dec. 31, 2015 AstraZeneca [Member]	Jan. 31, 2014 AstraZeneca [Member]	Dec. 31, 2013 AstraZeneca [Member] Upfront, milestone and other licensing payments [Member]	Jun. 30, 2014 AstraZeneca [Member] Amortization Income Expense [Member]	Jun. 30, 2013 AstraZeneca [Member] Amortization Income Expense [Member]	Jun. 30, 2014 AstraZeneca [Member] Amortization Income Expense [Member]	Jun. 30, 2013 AstraZeneca [Member] Amortization Income Expense [Member]	Jun. 30, 2014 AstraZeneca [Member] Assets Not Yet Transferred to Alliance Partner [Member]	Jun. 30, 2014 AstraZeneca [Member] Services Not Yet Performed For Alliance Partner [Member]	Dec. 31, 2016 AstraZeneca [Member] Amylin Related Products [Member]	Dec. 31, 2015 AstraZeneca [Member] Amylin Related Products [Member]	Mar. 31, 2017 AstraZeneca [Member] Amylin Related Products [Member] Maximum [Member]	Mar. 31, 2017 AstraZeneca [Member] Amylin Related Products [Member] Minimum [Member]	Jun. 30, 2014 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member]	Mar. 31, 2017 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Maximum [Member]	Dec. 31, 2016 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Maximum [Member]	Dec. 31, 2015 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Maximum [Member]	Dec. 31, 2014 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Maximum [Member]	Mar. 31, 2017 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Minimum [Member]	Dec. 31, 2016 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Minimum [Member]	Dec. 31, 2015 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Minimum [Member]	Dec. 31, 2014 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Minimum [Member]
Alliances and Collaborations Statement [Line Items]
Number of agreements in collaboration													3
Annual limit on development agreement costs					$ 227,000,000						$ 84,000,000	$ 127,000,000
Proceeds received at the closing of the transaction							2,700,000,000		2,700,000,000
Total contingent regulatory and sales-based milestone payments to be potentially received as consideration for the sale of a business							1,400,000,000		1,400,000,000
Total contingent approval milestones to be potentially received as consideration for the sale of a business							800,000,000		800,000,000
Total contingent sales-based milestones to be potentially received as consideration for the sale of a business							600,000,000		600,000,000
Maximum contingent payments if and when certain assets are transferred							225,000,000		225,000,000
Royalty rate on net sales																					2.00%	2.00%	12.00%	5.00%		25.00%	27.00%	35.00%	44.00%	12.00%	9.00%	7.00%	3.00%
Royalty rate sales threshold - Maximum																									500,000,000
Royalty rate sales threshold - Minimum																									500,000,000
Total consideration received during the period									3,600,000,000
Contingent regulatory milestone payments received during the period									700,000,000
Portion of the proceeds received allocated to the sale of the business									2,900,000,000
Portion of the proceeds received allocated to the undelivered elements of the sales transaction									667,000,000
Allocation of goodwill to disposal group									600,000,000
Reversal of net deferred tax liabilities attributed to the inside tax basis of Amylin									821,000,000
Earned royalties									169,000,000
Earned royalties included in other income	144,000,000	32,000,000	252,000,000	89,000,000					138,000,000
Earned royalties allocated to undelivered elements									31,000,000
Net product sales	2,770,000,000	3,024,000,000	5,577,000,000	5,981,000,000			2,000,000	431,000,000	161,000,000	786,000,000
Alliance and other revenues	1,119,000,000	1,024,000,000	2,123,000,000	1,898,000,000			26,000,000	5,000,000	45,000,000	9,000,000
Total revenues	3,889,000,000	4,048,000,000	7,700,000,000	7,879,000,000			28,000,000	436,000,000	206,000,000	795,000,000
Profit sharing - Cost of products sold							1,000,000	178,000,000	77,000,000	324,000,000
Cost of products sold-amortization of deferred income	(991,000,000)	(1,108,000,000)	(1,959,000,000)	(2,171,000,000)												(74,000,000)		(149,000,000)
Payments to/(from) alliance partners - Cost of products sold								(6,000,000)	(9,000,000)	(9,000,000)
Payments to/(from) alliance partners - Marketing, selling and administrative							4,000,000	(34,000,000)	(7,000,000)	(71,000,000)
Payments to/(from) alliance partners - Advertising and product promotion							(1,000,000)	(7,000,000)	(4,000,000)	(18,000,000)
Payments to/(from) alliance partners - Research and development							(2,000,000)	(21,000,000)	(9,000,000)	(43,000,000)
Other (income)/expense	(104,000,000)	199,000,000	(312,000,000)	180,000,000											(21,000,000)	(8,000,000)	(34,000,000)	(15,000,000)
Provision for restructuring	16,000,000	173,000,000	37,000,000	206,000,000				(20,000,000)	(2,000,000)	(25,000,000)
Royalties							(90,000,000)		(138,000,000)
Transitional services							(34,000,000)		(65,000,000)
Gain on sale of product lines, businesses, and assets	7,000,000		(252,000,000)	(1,000,000)			12,000,000		(247,000,000)
Deferred income - Cash Flow information			423,000,000	619,000,000			14,000,000		289,000,000	80,000,000
Proceeds from sale of business			3,159,000,000				99,000,000		3,154,000,000
Other investing activities			(160,000,000)	3,000,000			53,000,000		53,000,000
Deferred income	2,132,000,000		2,132,000,000			1,525,000,000													369,000,000	260,000,000
Deferred income from alliances included in liabilities related to assets held-for-sale														$ 3,671,000,000